The Week: AI, GLP-1s, and Scott's Iran War Reversal
Summary
Scott Galloway critiques the AI boom, citing rising costs and poor ROI as companies like Uber and Microsoft scale back investments. He contrasts this with Eli Lilly’s CEO, who argues GLP-1 drugs offer more transformative health benefits than AI. Galloway also retracts his support for military action in Iran, calling it a strategic failure. Finally, he shares advice on managing anxiety through immediate action.
Topics discussed
Sponsors: Odoo and Geico
Introduction: AI costs, Pharma, and Iran
The rising cost of AI and the dot-com bubble comparison
Ted Sarandos on AI in Hollywood and creativity
GLP-1 drugs and the broken US healthcare system
Sponsors: LinkedIn and Odoo
Scott rethinks support for military action in Iran
Algebra of Happiness: Action absorbs anxiety
Outro and Mint Mobile ad
Listen ad-free on Castria